Tech Company Financing Transactions
Astrocyte Pharmaceuticals Funding Round
On 8/21/2023, Astrocyte Pharmaceuticals landed $6 million in Series B funding from Alzheimer's Drug Discovery Foundation, Boston Harbor Angels and DeepWork Capital.
Transaction Overview
Company Name
Announced On
8/21/2023
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series B
Investors
Proceeds Purpose
Astrocyte intends to use the funds to accelerate the clinical development of AST-004, a promising therapeutic candidate aimed at treating a broad array of acute brain injuries including stroke and traumatic brain injury (TBI), and further assess its potential in preclinical models of Alzheimer's disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
93 Shennecossett Rd.
Groton, CT 06340
USA
Groton, CT 06340
USA
Phone
Website
Email Address
Overview
Astrocyte Pharmaceuticals Inc. is a small drug development company dedicated to clinically proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Korinek
Co-Founder
James Lechleiter
VP - Manufacturing
Russell Poe
VP - R & D
Theodore Liston
Browse more venture capital transactions:
Prev: 8/21/2023: Prins AI venture capital transaction
Next: 8/22/2023: Advanced NanoTherapies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs